News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Real-time Estimate Cboe BZX Other stock markets 10:06:00 2024-06-05 am EDT			5-day change	1st Jan Change
995.2 ^USD	+0.20%		+3.07%	+13.42%

Jun. 04	RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,185	MT
Jun. 03	FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,185	Jun. 04	MT
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier	Jun. 03	MT
FibroGen To Begin Trials on Tumor Treatment After FDA OK	Jun. 03	DJ
Fibrogen, Inc. Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals, Inc. to Evaluate FibroGen's Immuno-Oncology Assets, Fg-3175 (Anti-Ccr8), in Upcoming Clinical Trials	Jun. 03	CI
Sanofi - Dupixent recommended for EU approval by the CHMP to treat patients with COPD	Jun. 03	AQ
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review	May. 31	RE
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee	May. 31	MT
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months	May. 31	MT
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.	May. 31	DJ
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD	May. 31	GL
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD	May. 31	AQ
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD	May. 31	CI
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation	May. 31	GL
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation	May. 31	AQ
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation	May. 31	CI
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN	May. 30	PR
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing	May. 29	MT
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors	May. 29	PR
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer	May. 23	MT
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO	May. 23	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Summary

Filters